Syros’ SY-1365 Displays Punch Against Ovarian Cancer, Studies Show

Syros’ SY-1365 Displays Punch Against Ovarian Cancer, Studies Show
Syros Pharmaceuticals’ investigational compound SY-1365 showed potent anticancer activity in cell and animal models of ovarian cancer, giving the company momentum to move toward the Phase 1 trial it plans later this year. SY-1365 was also active against breast cancer and lung cancer, Syros said at the American Association of Cancer Research (AACR) 2017 Annual Meeting

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *